18 research outputs found
Breast cancer survival among young women: a review of the role of modifiable lifestyle factors
Urinary symptoms, quality of life, and patient satisfaction in genetic and sporadic hereditary spastic paraplegia
Possible role of hyposensitivity of Câfiber afferents at the proximal urethra in the development of urge urinary incontinence in patients with detrusor overactivity
Gender Difference in the Prognostic Role of Interleukin 6 in Oral Squamous Cell Carcinoma
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen
The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-specific. FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This prospective study is aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-rs4426527, -rs34116584 and del-74 bp), and to discover additional markers. CRC patients (n = 144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes. Grade â„2 neurotoxicity was associated false discovery rate-adjusted q-value <0.1) with single-nucleotide polymorphisms in ABCC1 (rs2074087: odds ratio = 0.43(0.22â0.86)), and ABCC2 (rs3740066: 2.99(1.16â7.70); rs1885301: 3.06(1.35â6.92); rs4148396: 4.69(1.60â13.74); rs717620: 14.39(1.63â127.02)). hMSH6-rs3136228 was associated with grade 3â4 neutropenia (3.23(1.38â7.57), q-value = 0.0937). XRCC3-rs1799794 was associated with grade 3â4 non-hematological toxicity (8.90(2.48â31.97), q-value = 0.0150). The markers previously identified in metastatic CRC were not validated. We have identified new markers of toxicity in genes of transport and DNA repair. If validated in other studies, they could help to identify patients at risk of toxicity